COMPANY PROFILE / iPS CELLS & REGENERATIVE MEDICINE
Intellia Therapeutics
A specialist in "in vivo genome editing": editing genes inside the body with a single infusion, without taking cells out
Intellia works with neither iPS cells nor cell transplantation. It earns a place in this field because it is the leading example of the approach at the opposite pole from therapies such as CASGEVY, which edit cells outside the body and put them back: editing directly inside the body. The company says it was the first in the world to take an in vivo genome-editing candidate into Phase 3. In April 2026 the HAELO Phase 3 trial met its primary endpoint and Intellia began a rolling BLA submission to the FDA. In October 2025, however, nex-z was placed on clinical hold. This profile concentrates on what the company invests in, who it works with and what it is aiming for.
- Intellia in 30 seconds, and where it stands in iPS cells and regenerative medicine
- The logo and how the name is written
- Where the company sits in iPS cells and regenerative medicine
- Company scale
- Resources committed to iPS cells and regenerative medicine
- Track record so far
- Plans ahead
- What the company is aiming for
- Partnership map for gene editing and cell therapy
- Technologies and products on offer
- The risks this company carries
- Glossary, references and claim-to-source audit
1. Intellia in 30 seconds, and where it stands in iPS cells and regenerative medicine
Massachusetts, U.S.40 Erie Street (cover of the 10-K)
(to the liver via LNP, single infusion)No iPS cell or cell transplant product of its own
nex-z (ATTR)Both in Phase 3. Not yet approved
Intellia is a specialist in "rewriting the genome directly inside the body" that handles neither iPS cells nor cell transplants. In its 10-K the company says it was the first in the world to advance an in vivo genome-editing candidate into Phase 3 Sourced.
We include it in this field because it is the leading example of the opposite approach to "ex vivo editing cell therapies such as CASGEVY", which are the main players in iPS cells and regenerative medicine: editing cells inside the body with a single infusion, without removing them. Note that Intellia itself has not stepped into the neighbouring territory of regenerative medicine, where cells are made and then transplanted Not yet confirmed.
2. The logo and how the name is written
A note on names: the legal entity is Intellia Therapeutics, Inc. We could not confirm an official Japanese-language rendering in the material we used, so this article uses the English name throughout. Regeneron Pharmaceuticals, its co-development partner, and Caribou Biosciences, from which it licensed the CRISPR/Cas9 patents, are both separate companies. It is also a separate legal entity from CRISPR Therapeutics, another "CRISPR company", which has its own profile in this series.
Official site: https://www.intelliatx.com/3. Where the company sits in iPS cells and regenerative medicine
| Therapeutic approach | Where Intellia fits | Status | Category |
|---|---|---|---|
| Genome editing (directly inside the body) | lonvo-z (KLKB1 gene) and nex-z (TTR gene). Delivered to the liver in lipid nanoparticles (LNPs) | Phase 3. A rolling BLA for lonvo-z is under way | Sourced |
| Genome editing (cells edited outside the body) | No product of its own is described. Licensed to AvenCell, Kyverna and others. Regeneron also holds non-exclusive rights to up to 10 ex vivo editing products | One AvenCell programme is in Phase 1 | Sourced |
| Allogeneic cell therapy (CAR-T) | Developed by AvenCell (a joint venture) and Kyverna (KYV-201). Intellia sits on the equity, milestone and royalty side | Led by the partners | Sourced |
| iPS-cell-derived cells | No mention of "iPS" in the 10-K or 10-Q | Could not be confirmed | Not yet confirmed |
| Viral gene delivery such as AAV | The main products use LNPs. No AAV-based product is described | - | Sourced |
| Mesenchymal stem cells and tissue engineering | Not described | Could not be confirmed | Not yet confirmed |
Our explainers on genome editing, off-target effects and safety assessment, lipid nanoparticles, transthyretin amyloidosis and CAR-T cells give the background to each row of the table.
4. Company scale
Figures are in U.S. dollars and the fiscal year ends in December. All of Intellia's revenue is revenue from collaboration agreements; it has no product sales Sourced.
| Measure (US$ millions) | 2024 | 2025 | First half of 2026 |
|---|---|---|---|
| Collaboration revenue | 57.9 | 67.7 | 22.7 |
| Research and development expense | 466.3 | 388.9 | 163.3 |
| General and administrative expense | 125.8 | 119.8 | 72.7 |
| Net loss | 519.0 | 412.7 | 202.9 |
| Cash and marketable securities (period end) | Not confirmed in the sources used | 605.1 | 628.4 |
Intellia had 377 employees at 13 February 2026 (263 mainly in R&D, and 106 with an M.D. or Ph.D.) Sourced. The 10-Q records that it cut its workforce in January 2025.
In April 2026 it raised equity, bringing in net proceeds of US$194.6 million (US$10.75 per share, 16,744,187 shares, including shares sold on exercise of the option to purchase additional shares) Sourced. General and administrative expense in the first half of 2026 was about US$16.5 million higher than a year earlier. The 10-Q attributes this to higher legal costs and to higher personnel and consulting costs as it builds up a commercial function.
The figures above are for the whole company. They do not measure the size of any iPS cell or regenerative medicine business. The company states plainly that all revenue to date has been collaboration revenue, and it has no product sales yet Sourced.
5. Resources committed to iPS cells and regenerative medicine
There are no figures for iPS cells and regenerative medicine alone. We show the company's resources as a genome-editing company, along four lines.
| Resource | Details | Category |
|---|---|---|
| People (company-wide) | 377 (13 February 2026): 263 in R&D and 106 with an M.D. or Ph.D. Workforce reduction in January 2025 | Sourced |
| People (iPS cells and regenerative medicine) | No dedicated team is described | Could not be confirmed |
| Sites | Headquarters in Cambridge (about 65,000 sq ft), with several research buildings in the same city. About 158,000 sq ft of office, laboratory and manufacturing space in Waltham (to be terminated by June 2028). About 125,000 sq ft at Technology Square in Cambridge, leased from September 2026 | Sourced |
| Money (R&D expense) | US$388.9 million company-wide (2025); US$163.3 million in the first half of 2026 | Sourced |
| Money (cash) | US$628.4 million (30 June 2026). Net proceeds of US$194.6 million from the April 2026 equity raise | Sourced |
| Investments and acquisitions | Acquired Rewrite Therapeutics (2022; about US$45.0 million upfront plus up to US$155.0 million in milestones, with a US$25.0 million research milestone paid in 2023). Equity in AvenCell (initially 33.33%, below 10% at the end of December 2025) and in Kyverna | Sourced |
| In-licensing | An exclusive licence from Caribou Biosciences to CRISPR/Cas9-related patents (2014; for human therapeutic use). It includes an exclusive sublicence of rights held by the University of California, the University of Vienna and Dr. Charpentier | Sourced |
| Out-licensing and collaboration | Regeneron (from April 2016): joint development of liver editing. Up to US$320.0 million in milestones per target and royalties up to the mid single-digit percent of sales. For nex-z in ATTR, development and promotion are shared, with Regeneron bearing about 25% of development costs and profits. Also agreements with AvenCell, Kyverna and ONK | Sourced |
| Universities, research institutes and public funding | The University of California and the University of Vienna as patent rights holders. No joint research agreements or grants relating to iPS cells are described | Sourced / could not be confirmed |
6. Track record so far
| When | What happened | What it means |
|---|---|---|
| May 2014 | Incorporated in Delaware (originally named AZRN, Inc.; renamed in July) | Started out as a CRISPR specialist |
| July 2014 | Obtains an exclusive licence to CRISPR/Cas9-related patents from Caribou Biosciences | Secured the rights to the editing tool |
| April 2016 | Licence and collaboration agreement with Regeneron (centred on liver editing) | Gained access to a genetics database and mouse models |
| December 2016 | Agreement with the University of California, the University of Vienna, Dr. Charpentier, Caribou, CRISPR Therapeutics and others to coordinate management of the core patents | The parties around the patents built a framework for cooperation |
| July 2021 | Co-founds AvenCell as a joint venture (allogeneic universal CAR-T) | Chose to put cell therapy into a joint venture |
| December 2021 | Licenses its ex vivo editing platform for allogeneic CAR-T to Kyverna (KYV-201) | Cell therapy led by the partner |
| 2022 | Acquires Rewrite Therapeutics (merged in September) | An acquisition combining upfront and contingent payments |
| 2024 | Starts the Phase 3 trial of nex-z in ATTR cardiomyopathy (MAGNITUDE). In November, the IND for the Phase 3 trial in ATTRv-PN (MAGNITUDE-2) is accepted | In vivo editing entered Phase 3 |
| January 2025 | First patient dosed in the HAELO Phase 3 trial. Workforce reduction | Concentrated resources on development |
| September 2025 | HAELO enrolment completed (80 people) | Recruitment for the pivotal trial finished |
| 29 October 2025 | The FDA places MAGNITUDE and MAGNITUDE-2 on clinical hold, after a patient showed Grade 4 liver enzyme and bilirubin elevations following dosing with nex-z. The patient died on 5 November | Safety of in vivo editing moved to the front |
| January and March 2026 | The FDA lifts the clinical holds on MAGNITUDE-2 (January) and MAGNITUDE (March) | Development resumed |
| April 2026 | Announces that the HAELO Phase 3 trial met its primary endpoint. Begins a rolling BLA submission to the FDA. Raises net proceeds of US$194.6 million in an equity offering | Moved into filing for approval |
| June 2026 | HAELO results published in NEJM | Peer-reviewed Phase 3 data |
| August 2026 | Reports that, in a genetic analysis of more than 600 samples, the highest liver enzyme values were concentrated in patients carrying particular HLA types | The search for the cause of the safety signal advanced |
7. Plans ahead
in the second half of 2026Rolling submission in progress. Not a guarantee of approval
first half of 2027If approved. The company's plan
the second half of 2026Phase 3 in ATTRv-PN
the FDAHLA typing results to be provided to participants
September 2026About 125,000 sq ft at Technology Square
Of the items in the table, the company gives timing for the lonvo-z BLA and launch and the MAGNITUDE-2 enrolment Sourced. All are plans, not guarantees of approval or launch Not yet confirmed.
None of the following appears in the material we used Not yet confirmed.
The price of lonvo-z / the timing of FDA approval / when the results of the nex-z Phase 3 trials will come / whether there is a causal link between HLA and liver enzyme elevation / any plan to enter iPS cells and regenerative medicine. Timings and prices in press reports cannot be verified against primary sources, so this article does not use them.
8. What the company is aiming for
This section includes things the company does not say directly. We set them out as inferences within what the primary sources support, with the evidence for each.
| What the evidence suggests | Primary information it rests on | Category |
|---|---|---|
| A policy of taking products all the way to launch itself | The 10-K says it will build an integrated commercial organisation. A lonvo-z launch is planned for the first half of 2027 | Sourced |
| By not removing cells, it is trying to avoid the burdens carried by ex vivo editing therapies (collecting cells, conditioning, shipping to a manufacturing site) | The 10-K says a single infusion, given in an outpatient setting. The primary sources contain no comparison with ex vivo editing therapies | Inference |
| It does not own cell therapy itself but spreads it through licensing | Licences to AvenCell, Kyverna and ONK, and to Regeneron for up to 10 ex vivo editing products. No cell therapy product of its own is described | Inference |
| The safety of in vivo editing is the biggest hurdle | The clinical hold in October 2025 and the HLA analysis disclosed in August 2026. No serious adverse events were reported in HAELO | Inference |
| An intention to extend beyond the liver to other tissues | The 10-K says it will advance gene editing in tissues other than the liver | Sourced |
We read the August 2026 disclosure as important to readers interested in regenerative medicine too, because it hints that the immune type (HLA) may be linked to the safety of in vivo editing Inference. According to the 10-Q, in the analysis of more than 600 samples the largest liver enzyme elevations were seen in patients with particular HLA types Sourced. HLA is the immune type that is the key to "rejection" in cell transplantation, and it is also the subject of our explainer on MHC and universal donors. The company has not explained how this result arises, however, and is in discussion with the FDA. We cannot conclude that HLA is the cause Not yet confirmed.
9. Partnership map for gene editing and cell therapy
The thing to notice in this map is that all of Intellia's involvement in cell therapy is on the "giving out" side. In AvenCell its stake, initially 33.33%, had fallen below 10% by the end of December 2025, and in Kyverna the partner bears development and costs Sourced.
10. Technologies and products on offer
| Product | How it works | Target | Status |
|---|---|---|---|
| lonvo-z (NTLA-2002) | Inactivates the KLKB1 gene in the liver inside the body. Delivered in LNPs as a single intravenous dose (50 mg) | Hereditary angioedema (HAE) | Phase 3 (HAELO) met its primary endpoint. Rolling BLA under way. RMAT, orphan and other designations |
| nex-z (NTLA-2001) | Inactivates the TTR gene in the liver inside the body. Delivered in LNPs as a single dose (55 mg) | ATTR amyloidosis (cardiomyopathy and polyneuropathy) | Phase 3 (MAGNITUDE, MAGNITUDE-2). Clinical holds lifted. Developed with Regeneron |
| Research programmes | Editing in tissues other than the liver, and new technologies such as DNA writing | - | Preclinical and research |
| Partners' cell therapies | Allogeneic CAR-T such as KYV-201 (Kyverna), using Intellia's ex vivo editing platform | Autoimmune diseases and others | Developed by the partners |
Trial results (figures from papers or the 10-Q, with comparator and time point)
| Trial | Population and design | Result | Time point and caveats |
|---|---|---|---|
| HAELO (Phase 3, NCT06634420) | HAE, ages 16 and older. 80 people randomised 2:1 (52 lonvo-z, 28 placebo), double-blind, a single 50 mg dose | Monthly attack rate from weeks 5 to 28 was 0.26 with lonvo-z and 2.10 with placebo (an 87% relative reduction). No serious adverse events in the lonvo-z group | Median follow-up 7.5 months (as of 10 February 2026). Placebo recipients can cross over to lonvo-z at week 28 |
| lonvo-z Phase 1/2 (10-K) | 32 people given 50 mg. Single-arm, no comparison group | Mean reduction in plasma kallikrein of 89% at 24 months. 31 people (97%) were attack-free and off long-term prophylaxis (at the data cut) | No comparison group. Data as of 29 August 2025 |
| nex-z Phase 1, ATTR-CM (10-Q) | 36 people. Single-arm | Mean reduction in serum TTR of 87% in the 9 people who reached 36 months | As of 23 August 2025. A non-randomised, after-the-fact comparison with a separate group of 1,792 people under the same conditions, including mortality, is also described (not randomised) |
| nex-z Phase 1, ATTRv-PN (10-Q) | 33 people at 0.3 mg/kg or higher. Single-arm | Mean reduction in serum TTR of 92% at 24 months (90% in the 12 people who reached 36 months) | Grade 3 or higher liver enzyme elevations in 3 people (not serious; resolved on their own) |
Intellia's therapy is not a cell but a drug in which Cas9 mRNA and guide RNA are packaged in lipid nanoparticles (LNPs) Sourced. There is no need to freeze living cells and ship them, and the manufacturing process comes closer to chemical manufacturing: synthesising nucleic acids, then mixing and purifying lipids Inference.
The 10-K says that drug substance, drug product, viral vectors and edited cells are supplied through outside manufacturers and its own capacity, and are made in GMP facilities Sourced. What determines quality is the composition and purity of the lipids, the uniformity of particle size, and the synthetic purity of the mRNA and guide RNA, which are different kinds of material from the culture media, scaffolds and cryopreservation media that matter in ex vivo editing cell therapies.
11. The risks this company carries
| Risk | Details | Category |
|---|---|---|
| Safety (nex-z) | The FDA placed a clinical hold in October 2025. A patient who showed Grade 4 liver enzyme elevation after dosing died (according to the treating physician, the cause of death was septic shock following a perforated duodenal ulcer, and the course also included acute liver injury and its steroid treatment). The hold has been lifted, but the company is in discussion with the FDA about the link with HLA | Sourced |
| No product yet | Collaboration revenue only, and no approved product. Approval and launch of lonvo-z is the first hurdle | Sourced |
| Cash burn | Net loss for the first half of 2026 was US$202.9 million. It has been covered by equity raises, and the company states that it may need to raise more funds | Sourced |
| Patents | The core patents obtained through Caribou are subject to interference proceedings with the Broad Institute, ToolGen and Sigma-Aldrich. The 10-K states that if any of them prevails, it could assert its rights against commercialisation of Intellia's products | Sourced |
| Long-term safety | The 10-K lists as risks unexpected adverse events and the potentially permanent nature of the effects of genome editing | Sourced |
| Partner's direction | The technology collaboration with Regeneron runs through April 2026, and we could not confirm an extension in the material we used | Sourced / not yet confirmed |
12. Glossary
- In vivo editing
- A method in which a drug is infused and edits cells directly inside the body. No cells are taken out.
- LNP (lipid nanoparticle)
- A tiny particle made of lipids that wraps nucleic acids and delivers them into cells.
- KLKB1 / kallikrein
- The gene that makes plasma kallikrein, which is involved in HAE attacks, and the enzyme itself.
- HAE (hereditary angioedema)
- An inherited disease with repeated attacks of swelling.
- ATTR (transthyretin amyloidosis)
- A disease in which a protein called TTR builds up in tissues. It has cardiomyopathy and polyneuropathy forms.
- BLA
- Biologics License Application, the U.S. application for approval of a biologic. A rolling submission sends in completed sections one by one.
- Clinical hold
- An order from the FDA to stop a clinical trial, for reasons such as safety.
- HLA
- The immune type, a set of markers by which the immune system tells "self" from "other". It is involved in transplant rejection.
- Allogeneic CAR-T
- A cell therapy in which a healthy donor's T cells are given a receptor that targets cancer or other cells, so that one batch can be used for many patients.
- RMAT
- Regenerative Medicine Advanced Therapy designation, an FDA programme that speeds up the development of regenerative medicine. Gene therapies can qualify too.
13. References
- Intellia Therapeutics Form 10-K for the fiscal year ended December 31, 2025 (filed with the U.S. SEC on 26 February 2026). Business overview, clinical work on lonvo-z and nex-z, agreements with Regeneron, AvenCell and Kyverna, patents, headcount, sites and financials. https://www.sec.gov/Archives/edgar/data/1652130/000119312526076550/ntla-20251231.htm
- Intellia Therapeutics Form 10-Q for the quarterly period ended June 30, 2026 (filed with the U.S. SEC on 6 August 2026). HAELO Phase 3 results, the rolling BLA, lifting of the nex-z clinical holds, the HLA analysis, and first-half 2026 financials. https://www.sec.gov/Archives/edgar/data/1652130/000119312526337952/ntla-20260630.htm
- ClinicalTrials.gov NCT06634420, HAELO: a Phase 3 study evaluating NTLA-2002 in hereditary angioedema (HAE). Start date 15 January 2025, 80 enrolled, primary endpoint the time-normalised number of confirmed HAE attacks. https://clinicaltrials.gov/study/NCT06634420
- ClinicalTrials.gov NCT06128629, MAGNITUDE: a Phase 3 study evaluating NTLA-2001 in ATTR cardiomyopathy. Estimated enrolment 1,200, primary endpoint a composite of cardiovascular death and cardiovascular events. https://clinicaltrials.gov/study/NCT06128629
- ClinicalTrials.gov NCT06672237, a Phase 3 study evaluating NTLA-2001 in ATTRv-PN (MAGNITUDE-2). Estimated enrolment 60, primary endpoints mNIS+7 and serum TTR. https://clinicaltrials.gov/study/NCT06672237
- N Engl J Med (indexed in PubMed) Cohn DM et al., "Lonvoguran Ziclumeran - In Vivo CRISPR Gene Editing in Hereditary Angioedema," N Engl J Med 2026 (published online 13 June 2026). Results of the HAELO Phase 3 trial. https://pubmed.ncbi.nlm.nih.gov/42294842/
- Intellia Therapeutics Official website (used to check the company overview and the logo). https://www.intelliatx.com/
14. Claim-to-source audit
| Claim in the article | Category | Source |
|---|---|---|
| Legal name, headquarters location (Cambridge), Nasdaq: NTLA, founded in May 2014 | Sourced | References 1 and 7 https://www.sec.gov/Archives/edgar/data/1652130/000119312526076550/ntla-20251231.htm https://www.intelliatx.com/ |
| Collaboration revenue, R&D expense, G&A expense and net loss (2024 and 2025), cash (end of 2025) | Sourced | Reference 1 https://www.sec.gov/Archives/edgar/data/1652130/000119312526076550/ntla-20251231.htm |
| First-half 2026 financials, cash of US$628.4 million, net proceeds of US$194.6 million from the equity raise, and the reason for higher G&A expense | Sourced | Reference 2 https://www.sec.gov/Archives/edgar/data/1652130/000119312526337952/ntla-20260630.htm |
| 377 employees (13 February 2026), 263 in R&D, and the January 2025 workforce reduction | Sourced | References 1 and 2 https://www.sec.gov/Archives/edgar/data/1652130/000119312526076550/ntla-20251231.htm https://www.sec.gov/Archives/edgar/data/1652130/000119312526337952/ntla-20260630.htm |
| Sites (Cambridge, Waltham, Technology Square) | Sourced | Reference 1 https://www.sec.gov/Archives/edgar/data/1652130/000119312526076550/ntla-20251231.htm |
| Exclusive licence from Caribou (2014) and the rights of the University of California, the University of Vienna and Dr. Charpentier | Sourced | Reference 1 https://www.sec.gov/Archives/edgar/data/1652130/000119312526076550/ntla-20251231.htm |
| The Regeneron agreements (2016; up to US$320.0 million per target; about 25% share for nex-z) | Sourced | References 1 and 2 https://www.sec.gov/Archives/edgar/data/1652130/000119312526076550/ntla-20251231.htm https://www.sec.gov/Archives/edgar/data/1652130/000119312526337952/ntla-20260630.htm |
| AvenCell (initially 33.33%, below 10% at the end of December 2025), Kyverna (KYV-201), and the terms of the Rewrite acquisition | Sourced | Reference 1 https://www.sec.gov/Archives/edgar/data/1652130/000119312526076550/ntla-20251231.htm |
| The existence of an agreement with ONK Therapeutics (content could not be confirmed) | Sourced | Reference 2 https://www.sec.gov/Archives/edgar/data/1652130/000119312526337952/ntla-20260630.htm |
| How lonvo-z and nex-z work (in vivo editing, LNP, single dose) and their Phase 3 status | Sourced | References 1 and 2 https://www.sec.gov/Archives/edgar/data/1652130/000119312526076550/ntla-20251231.htm https://www.sec.gov/Archives/edgar/data/1652130/000119312526337952/ntla-20260630.htm |
| HAELO Phase 3 results (80 people, 0.26 versus 2.10, an 87% relative reduction, no serious adverse events) | Sourced | References 2, 6 and 3 https://www.sec.gov/Archives/edgar/data/1652130/000119312526337952/ntla-20260630.htm https://pubmed.ncbi.nlm.nih.gov/42294842/ https://clinicaltrials.gov/study/NCT06634420 |
| lonvo-z Phase 1/2 (32 people, mean kallikrein reduction of 89%, 31 attack-free) | Sourced | Reference 1 https://www.sec.gov/Archives/edgar/data/1652130/000119312526076550/ntla-20251231.htm |
| nex-z Phase 1 (ATTR-CM: 36 people, 87% reduction in the 9 people at 36 months; ATTRv-PN: 33 people, 92% reduction at 24 months) | Sourced | Reference 2 https://www.sec.gov/Archives/edgar/data/1652130/000119312526337952/ntla-20260630.htm |
| Design and enrolment status of the MAGNITUDE and MAGNITUDE-2 Phase 3 trials | Sourced | References 2, 4 and 5 https://www.sec.gov/Archives/edgar/data/1652130/000119312526337952/ntla-20260630.htm https://clinicaltrials.gov/study/NCT06128629 https://clinicaltrials.gov/study/NCT06672237 |
| The FDA clinical hold of 29 October 2025, its lifting in January and March 2026, and the patient's death (5 November) | Sourced | References 1 and 2 https://www.sec.gov/Archives/edgar/data/1652130/000119312526076550/ntla-20251231.htm https://www.sec.gov/Archives/edgar/data/1652130/000119312526337952/ntla-20260630.htm |
| Disclosure of the August 2026 HLA analysis (more than 600 samples) | Sourced | Reference 2 https://www.sec.gov/Archives/edgar/data/1652130/000119312526337952/ntla-20260630.htm |
| Start of the rolling BLA (April 2026), the launch plan (first half of 2027), and expected completion of MAGNITUDE-2 enrolment (second half of 2026) | Sourced | Reference 2 https://www.sec.gov/Archives/edgar/data/1652130/000119312526337952/ntla-20260630.htm |
| Interference proceedings (Broad, ToolGen, Sigma-Aldrich) and the possibility that rights are asserted | Sourced | Reference 1 https://www.sec.gov/Archives/edgar/data/1652130/000119312526076550/ntla-20251231.htm |
| The three types of company (large pharma and strategic partners / genome editing and gene therapy / iPS cell and cell therapy) | Our calculation | This article's own classification. Example companies are drawn from those covered in this series |
| Use of iPS cells, mesenchymal stem cells, and any cell therapy product of its own | Not yet confirmed | References 1 and 2 https://www.sec.gov/Archives/edgar/data/1652130/000119312526076550/ntla-20251231.htm https://www.sec.gov/Archives/edgar/data/1652130/000119312526337952/ntla-20260630.htm Not stated in the 10-K or 10-Q. This article does not conclude that they do not exist either |
| The price and approval timing of lonvo-z, timing of nex-z Phase 3 results, and a causal link between HLA and liver enzyme elevation | Not yet confirmed | Reference 2 https://www.sec.gov/Archives/edgar/data/1652130/000119312526337952/ntla-20260630.htm Not stated in the 10-Q. Figures from press reports are not used |
| Extension of the technology collaboration with Regeneron | Not yet confirmed | Reference 1 https://www.sec.gov/Archives/edgar/data/1652130/000119312526076550/ntla-20251231.htm The term runs to April 2026. An extension could not be confirmed in the material we used |
| The reading that it is trying to avoid the burdens of ex vivo editing | Inference | Reference 1 https://www.sec.gov/Archives/edgar/data/1652130/000119312526076550/ntla-20251231.htm This article's interpretation |
| The reading that it spreads cell therapy through licensing rather than owning it | Inference | Reference 1 https://www.sec.gov/Archives/edgar/data/1652130/000119312526076550/ntla-20251231.htm This article's interpretation |
| The reading that the safety of in vivo editing is the biggest hurdle | Inference | Reference 2 https://www.sec.gov/Archives/edgar/data/1652130/000119312526337952/ntla-20260630.htm This article's interpretation |
| The reading that the HLA result links immune type to the safety of in vivo editing | Inference | Reference 2 https://www.sec.gov/Archives/edgar/data/1652130/000119312526337952/ntla-20260630.htm This article's interpretation. The company has not explained the mechanism |
| The reading that manufacturing comes closer to chemical manufacturing: synthesising nucleic acids, then mixing and purifying lipids | Inference | This article's interpretation (from a materials and process viewpoint) |
Last updated 1 October 2026 / Troy Technical
Every figure in this article comes from the statutory filings Intellia has made with the U.S. Securities and Exchange Commission (SEC), ClinicalTrials.gov and peer-reviewed papers. No research-firm estimates or press-based figures have been used. Passages marked "Inference" are this article's interpretation of the primary sources, not statements made by the company. This article summarises a company's activities; it does not recommend any treatment and is not medical advice.